Analysis on the market scale and pattern of contrast agents in China in 2021: Jiangsu Hengrui pharmaceutical, general electric, Yangzijiang Pharmaceutical Group, Bayer and bleco account for more than

One 、 summary

contrast agent （ Also known as contrast agent ,contrastmedia） It is injected to enhance the effect of image observation （ Or take ） Chemicals into human tissues or organs . The density of these products is higher or lower than that of the surrounding tissues , The resulting contrast shows the image with certain instruments . Contrast agents can be divided into two categories , High atomic weight 、 It is lower than the significant high-density contrast agent and atomic weight 、 Low density contrast agent with low specific gravity .

Contrast agent classification

source ： Zhiyan consultation and arrangement

Two 、 The size of the market

Contrast agent is one of the most commonly used drugs in interventional radiology , It is mainly used for blood vessels 、 Display of body cavity , recently , A matter of great concern 2021 The adjustment of the national medical insurance drug catalogue in has come to an end , Two contrast agent products, Perfluorobutane microspheres for injection and perfluoropropane human albumin microspheres for injection, were included in the medical insurance catalogue through negotiation . not long ago , Zhengda Tianqing Pharmaceutical Group's disodium gadolinate injection has been approved as a supplementary application , Become the second evaluated enterprise of the product . Besides , With the implementation of the fifth batch of centralized purchase , The two bid winning varieties of iohexol injection and ioxamol injection will make waves again ,2020 Chinese urban public hospitals 、 County level public hospitals 、 Urban community centers and township health centers （ Short for Chinese public medical institutions ） The sales of terminal contrast agents are made up of 2016 Years are not enough 100 Billion yuan up to 2019 In more than 150 One hundred million yuan ,2020 A slight decline in ,2021H1 Year-on-year growth exceeding 25%.

2018-2020 Statistics of terminal contrast agent sales of public medical institutions in China

source ： Minenet 、 Zhiyan consultation and arrangement

2021 Since then , existing 3 Contrast agents were approved for marketing , Nanjing Hairong Pharmaceutical Co., Ltd | Rui Jia nuosheng injection of Nanjing Hairong Medical Technology Co., Ltd 、 Shandong Kelun Pharmaceutical Co., Ltd.'s iodine paxtol injection 、 The disodium gadolinium selenate injection of Hunan Kelun Pharmaceutical Co., Ltd . Regalosan injection is the first selective adenosine injection in the world A2a Receptor agonists , By selectively activating adenosine A2a Receptors dilate coronary arteries , Increase coronary blood flow for MPI Loading drugs , Selective coronary artery dilatation 、 It works quickly 、 Fixed dose administration, etc . Regalosan injection 2008 year 4 Won the United States in June FDA Approval for listing , The original research is not listed in China .2021 year 10 month , Nanjing Hairong Pharmaceutical Co., Ltd | Nanjing Hairong medical technology won the first imitation , This is also the second generic drug product of the company that is the first listed in China . It is worth mentioning that , This product is a national product “ Major new drug creation ” Support varieties for major science and technology projects in the 13th five year plan , It fills the blank of myocardial perfusion imaging in China . Iodopatol is Italian Bracco Developed nonionic monomer contrast agent , For neuroradiology related angiography 、 Angiography 、 Digital subtraction angiography 、 Urography 、CT Enhanced scanning during inspection, etc .2021 year 6 month , Colleen announced , The subsidiary, Shandong Kelun Pharmaceutical Co., Ltd., approved the listing of iodine palmitol injection , This product is the first drug approved by collen to enter the field of diagnostic angiography .9 month , The disodium gadolinium selenate injection of Hunan Kelun pharmaceutical has been approved for marketing , This is the second contrast agent approved by collen , It is also the second domestic enterprise of the product .

2021 Since, it has been approved to market as a contrast agent product

source ： Minenet 、 Zhiyan consultation and arrangement

By 2021 year 12 month 6 Japan ,7 Contrast agent products have been evaluated by enterprises , among , Iohexol injection and ioxamol injection have been included in the fifth batch of centralized purchase , Iodopatol injection and disodium gadolinium selenate injection have met 3 Competitive conditions at home and above （3 Family reviews or 2 Home review +1 Jiayuanyan ）. Besides , also 3 The supplementary application for conformity evaluation of products is under review and approval , They are iohexol injection of Ningbo Tianheng pharmaceutical of Fu'an Pharmaceutical Group 、 Meglumine gadolinate injection of Jiangsu Hengrui Pharmaceutical Co., Ltd 、 Beijing Beilu Pharmaceutical Co., Ltd.'s iodine Paxil injection .

Over evaluation of contrast media

source ： Minenet 、 Zhiyan consultation and arrangement

2018 Since, there have been 13 The production of contrast media is under review and approval , among , Gadolinium butoxide injection is the most popular , Yes 4 companies ; Iodopatol injection 、 Meglumine gadolinate injection 、 Poppy ethyl iodized oil injection, etc 5 All products have 2 Enterprises report production . Besides , Iopromide injection 、 Gadolinium butoxide injection 、 No domestic generic drug enterprises such as gadolinol injection have been approved , Involving Jiangsu Hengrui medicine 、 Chengdu Beite Pharmaceutical Co., Ltd 、 Hunan Kelun Pharmaceutical Co., Ltd 、 Yangzi River Pharmaceutical Group, Guangzhou Hairui pharmaceutical and other enterprises .

2018 Year to date, the production of contrast media is under review

source ： Minenet 、 Zhiyan consultation and arrangement

3、 ... and 、 Market structure

stay 2021 In the first half of, the terminal contrast agent products of public medical institutions in China TOP10 in ,3 The sales of products exceed 10 One hundred million yuan . Iodixanol injection in excess of 20 The sales volume of billion yuan ranks first , Iohexol injection 、 Iodofol injection followed closely , In the second 、 Third . In terms of growth rate ,10 All products have exceeded double-digit growth , among , Iodomeprazole injection increased by an astonishing amount , the height is 196.05%, Get into the top ten ; Sulfur hexafluoride microbubbles for injection and iodixanol injection rose by more than 40%.

2021 In the first half of, the terminal contrast agent products of public medical institutions in China TOP10 Statistics

source ： Minenet 、 Zhiyan consultation and arrangement

From the perspective of the manufacturer , stay 2021 In the first half of, the terminal contrast agent brands of public medical institutions in China TOP10 in ,2 The sales of brands exceed 10 One hundred million yuan . Hengrui pharmaceutical 、 Ge 、 Yangzi River Pharmaceutical Group, etc 4 Each company has 2 Brands on the list .

2021 In the first half of, the terminal contrast agent brands of public medical institutions in China TOP10 Statistics

source ： Minenet 、 Zhiyan consultation and arrangement

2021 Jiangsu Hengrui Pharmaceutical Co., Ltd 、 Ge 、 Yangzi River Pharmaceutical Group 、 Bayer 、 Bleco is in the top five , The total market share exceeds 80%, The industry concentration is relatively concentrated ; Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. has surpassed 200% The strong growth rate rose to the eighth place , yes TOP10 The fastest growing manufacturer in China .

2021 The competition pattern of Chinese contrast agent market in the first half of

source ： Minenet 、 Zhiyan consultation and arrangement